ASCO 2024 preview – two strikes against USP1
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Tango cans TNG348 while Roche’s KSQ-4279 looks virtually inactive.
Petosemtamab meets sellside forecasts, but for the bull case you need to include an unconfirmed response.
The conference’s abstract drop features ASC4First in its plenary session.
An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.
Plenty of questions remain about the latest palazestrant data drop as investors hope for a Novartis buyout.
Hopes are high for petosemtamab head and neck data at ASCO, but what does a win look like?
Abstract titles reveal some of ASCO’s key datasets.